
Losses have narrowed at Cramlington's Pharmaron amid a year of continued investment in the site.
New results for the Chinese-owned business - formerly called Aesica - show operating losses fell from £24.4m to £13.7m in 2023 as revenues rose from £5.09m to £7.48m. Bosses said the Windmill Industrial Estate firm, which specialises in the production of active pharmaceutical ingredients, has the backing of its parent company, Beijing-based life sciences giant Pharmaron, in planned expansion.
The firm has posted operating losses since 2020 when it suffered a temporary shutdown of all production owing to a "significant, unexpected incident". But that has not stopped Pharmaron, which acquired the facility in early 2022, from eyeing development of the site, which employs about 140 people.
Read more: ScS boss Steve Carson to step down having steered retailer through Italian takeover
Read more: North East technology entrepreneurs come together for new firm
In the latest accounts, Pharmaron said it was reviewing plans to develop the Northumberland location and that it had approved £5m of investment into the 177,000 sqft factory, including its technical capabilities. The firm said it has a long term ambition to improve the flexibility of the site meaning it can accommodate shorter production runs as well as long term contracts
Elsewhere in the accounts, directors pointed to a number of exceptional items that made up recent losses but which it said did not reflect underlying performance. Those included £4.3m of costs associated with Pharmaron's acquisition in 2022; a £1.2m hit created by mutual agreement with the firm's largest customer to cancel its contract and stop production, again in 2022; and in 2023, releases of an onerous contract liability totalling £100,000.
During the 2023 year under review, the plant drew the majority of its revenue from the UK market (£3.1m), a change on the previous year when the UK constituted only £1.2m of revenue and the rest of the world made up £2.5m, compared with £1.5m last year.
In documents attached to the accounts, Pharmaron director Stephen Lewinton said: "The long-term strategic plan for the site is to increase operational flexibility, so that both shorter production runs as well as semi-continuous and long-term production can be supported, to service a wider group of clients. This will involve reconfiguration of both operations and infrastructure over a period. The business development team will work closely with the site to maximise the potential revenue streams available.